James Huang is the Founding Managing Partner of Panacea Venture. James has over 30 years of experience in the healthcare industry across Asia and the US. Prior to founding Panacea, James joined Kleiner Perkins in 2011 as a Managing Partner, focusing on life science investments in the Greater China region. Before that, James was a Managing Partner at Vivo Ventures and President of Anesiva, a biopharmaceutical company focused on pain-management treatments. James has also held a number of senior positions across business development, marketing, and R&D functions with world leading healthcare companies, including Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb, and ALZA Corp. (acquired by Johnson & Johnson).

James holds an M.B.A. from Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

Andrew Aherrera is a Partner at Panacea, and leads the fund’s public markets strategy that encompasses de novo investments in both publicly traded companies as well as crossover opportunities. Prior to joining Panacea, Andrew was previously Portfolio Manager of Ample Plus, a healthcare-dedicated crossover investment fund with a similar cross-border pedigree that he helped build from the ground up, while simultaneously maintaining an operational role spanning business development, alliance management, and capital markets efforts at the fund’s biotech incubation engine. Andrew began his investment career at RA Capital, primarily covering CNS, hepatology, and oncology therapeutic areas.

Andrew graduated from the combined MD/MBA program at Tufts University School of Medicine, where he garnered AOA Honors and matched into Plastic Surgery at New York Presbyterian/Weill Cornell & Columbia University Medical Centers.

Benjamin joined Panacea Venture in 2018, he is a scientist, entrepreneur, investor and merchant banker. Most recently Benjamin served as the CEO of ImaginAb, Inc. a ventured backed company developing a cutting edge platform to address an urgent unmet need in immuno-oncology. Immediately before that, he was the Chairman and CEO of London based Immune Targeting Systems, Inc. leading the immune therapy company through significant strategic growth, innovative product development and establishing a presence in France and North America. Prior to returning to operational roles, he spent nine years as a Managing Director at Burrill & Company, a global life sciences venture firm where he evaluated investment opportunities and assisted a global clientele in completing licensing, partnering and M&A transactions. He also played a key role in establishing the Malaysian Life Sciences Fund I and served as a director. Earlier in his career as an R&D executive, he has experience in building talented research team in immunology, stem cell biology, genomics, gene therapy and molecular diagnostics in both biotechnology start-ups and multinational pharmaceutical companies including Roche Diagnostics and Novartis.

Ben received his academic training in Microbiology and Immunology at the University of Wisconsin-Madison and Stanford University. Benjamin resides in the San Francisco Bay Area.

Cheryl Bao is a Partner and Chief Legal Officer with Panacea. Prior to joining Panacea, Cheryl previously worked as an attorney at two prestigious US law firms’ Shanghai office for 11 years, focusing mainly on venture capital and private equity investment practice. Cheryl holds an LL.M degree from University of Pennsylvania School of Law and an LL.M/LL.B degree from Shanghai University of International Business and Economics. Cheryl is a New York licensed attorny and has passed the Chinese Judicial Examination.

Delia Ding is a Partner and Chief Financial Officer with Panacea. Delia is responsible for daily financial functions on fund operation.  She is also a Finance Director at Kleiner Perkins Caufield & Byers China.

Before joining KPCB in the year of 2013, Delia Ding worked at KPMG Shanghai and KCS Management & Consultancy where she had more than 10 years advisory and management experience on financial, taxation and human resources areas.

Delia received her bachelor’s degree in Accounting from Tongji University in China.

Andrew Ng is a Partner with Panacea. Andrew has over 13 years of experience in the healthcare industry across Asia and the US. He has established the healthcare investment practice of VMS Group in 2017 and invested in 10+ growth-stage investments across the therapeutics, diagnostics, medical device and CRO/CDMO verticals.

Prior to joining Panacea, Andrew was responsible for the China Healthcare Equity Research at Barclays Capital based in Hong Kong. Before that, he was an investment banker covering healthcare clients across the Asia Pacific region at Barclays Capital with a focus in healthcare cross-border M&A. Andrew started his career as a management consultant at ZS Associate in the United States advising global pharma on sales & marketing strategy and operations.

Andrew holds an M.B.A from INSEAD, a M.Eng. degree and a B.S. degree in Operations Research & Engineering from Cornell University.

Jeffry Wu is a Partner with Panacea. Prior to joining Panacea, Jeffry worked for Johnson & Johnson’s corporate venture (JJDC) and private equity funds in the United States and China dedicated to life science investments. He is also a member of the CFA Institute and served on the board of several healthcare companies.

Jeffry has graduated from University of Science & Technology of China and holds a PhD degree from Columbia University in the US and an M.B.A from INSEAD in France.

Fay Xing is a partner at Panacea and is passionate about working with scientists and entrepreneurs at earliest stages of company formation.  She has over 15 years of experience in company building, operations and cross-border investment in the US and China.  Prior to Panacea Venture, she was a partner at 6 Dimensions Capital/WuXi Healthcare Ventures, co-head/managing director of pharma/biotech at CBC group, and principal at Decheng capital.  She invested in therapeutics, medtech and digital health startups and incubated new companies including digital health startup PICA health, where she was the founder and CEO. Prior to entering venture capital, she worked in marketing and new ventures at Medtronic.  

She was trained as a physician and scientist.  She has a BA in biochemistry from Columbia, MD from Stanford and a MBA from Harvard. 

Debra Yu is a Partner and Chief Operating Officer of Panacea Venture. Debra has over 30 years of experience in the healthcare industry and has worked in US, Europe and China. She has held leadership roles in venture capital, investment banking, business development, alliance management and strategy. Previously, she was President and Chief Strategy Officer of LianBio and Managing Director Cross-border Investment Banking at China Renaissance where she built key activities from the ground up and was instrumental in creating first-of-its-kind strategic transactions. She founded and ran Labrador Advisors, a business development advisory firm where she worked with small biotech and medtech companies, as well as multinational pharma companies.  Earlier in her career, she helped to architect and co-lead Pfizer’s corporate venture group and was a General Partner at Bay City Capital and Delphi Ventures, two leading bay area life science focused venture capital firms. Debra began her career at McKinsey and Morgan Stanley.

Debra holds an M.D.  from Harvard Medical School and a B.A. degree in molecular biology from Princeton University. 

Nikki Zhang is a Partner with Panacea Venture. Nikki has over 12 years of extensive working experience in biotech, medical device and healthcare investment industries across Asia and the US. Since she started her venture career, Nikki has invested in 10+ early-to-growth stage companies across pharma/biotech, medical device, diagnostics and CRO/CDMO sectors.

Before joining Panacea, Nikki was a director at Kleiner Perkins, covering the firm’s healthcare investment and portfolio management in Asia. Prior to Kleiner Perkins, Nikki worked at Zimmer Biomet Inc. in the US, where she took multiple leadership roles to manage the company’s global trauma business, M&A and post-merger integration projects. Earlier in her career, Nikki was a business development manager at HUTCHMED, where she specialized in corporate strategy, business development and strategic partnership management.

Nikki holds an M.B.A. from The Fuqua School of Business of Duke University. She also received an M.A. in Biotechnology from Columbia University and a B.S. in Biochemistry from The University of Texas at Austin.